Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.40 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26203820 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL27056796 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9973391 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL18751717 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL9973396 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL26203818 | 1.00 | CES2 (0.48) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL17992598 | 0.97 | CES2 (0.44) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL1667685 | 0.90 | CES2 (0.39) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950237 | 0.89 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A | |
| SCHEMBL23950236 | 0.89 | CES2 (0.64) | CES2MEN1FAAHMAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-11840691-B2 | Compound and application thereof | KYLONOVA (XIAMEN) BIOPHARMA CO., LTD. (CN) | 2023-12-12 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-11746120-B2 | Stat degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-07-29 | — | — | US | disclosed |
| US-9382540-B2 | Compositions and methods for modulating angiopoietin-like 3 expression | ISIS PHARMACEUTICALS, INC (US) | 2016-07-05 | — | — | US | disclosed |
| US-20160017323-A1 | CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE | ISIS PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-8202902-B2 | Bivalent SMAC mimetics and the uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-06-19 | — | — | US | disclosed |
| US-7960372-B2 | Inhibitors of apoptosis proteins; antiproliferative agents; kits | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | AEGERA THERAPEUTICS, INC. (CA) | 2010-08-12 | — | — | US | disclosed |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-05-14 | — | — | US | disclosed |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | CES2 3880/4885MEN1 2268/4885FAAH 2976/4885 |
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CES2 953/4885MEN1 2085/4885FAAH 3544/4885 |
| US-20100203012-A1 | IAP BIR DOMAIN BINDING COMPOUNDS | BIRC5, BIRC2, BIRC3 | CES2 4871/4885MEN1 1726/4885FAAH 4757/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-11746120-B2 | Stat degraders and uses thereof | STAT4, STAT1, STAT3 | CES2 2122/4885MEN1 3280/4885FAAH 3098/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-20080089896-A1 | Bivalent SMAC mimetics and the uses thereof | BID, BAD, BIRC2 | CES2 4721/4885MEN1 1010/4885FAAH 4543/4885 |
| US-20210228562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-20090123480-A1 | BIVALENT SMAC MIMETICS AND THE USES THEREOF | BID, BAD, BIRC2 | CES2 4721/4885MEN1 1010/4885FAAH 4543/4885 |
| US-20230398223-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-11840691-B2 | Compound and application thereof | GALNT6, GALNT3, GALNT14 | CES2 3035/4885MEN1 4080/4885FAAH 4700/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CES2 1669/4885MEN1 4055/4885FAAH 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.